Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)

Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR) is a phase 3, randomised interventional study registered as NCT07070622 by West China Hospital, with a registry enrolment figure of 186 participants, started 2024-11-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: patients were assigned to receive TNT or iTNT management. Conditions listed: Rectal Cancer. Primary outcome: organ preservation rate，OPR. Colorectal eligibility wording from the registry: "rectal adenocarcinoma confirmed by pathology and pMMR/MSS by immunohistochemistry and/or genetic testing;". Sites: China. No results are recorded here; the registry entry is the source.